Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [2] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [2] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [2] Upcoming Investor Conferences - Ligand management will participate in the H.C. Wainwright Royalty Company Conference on May 13, 2025, at 3:30 p.m. ET, including a fireside chat and one-on-one meetings [4] - Management will also take part in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, at 2:05 p.m. ET, featuring a fireside chat and one-on-one meetings [4] - Additionally, Ligand will engage in one-on-one meetings at the Craig-Hallum Institutional Investor Conference on May 28, 2025 [4] Technology Platforms - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [2] - The Captisol® platform is designed to optimize the solubility and stability of drugs through a chemically modified cyclodextrin structure [2] - The NITRICIL™ platform allows for tunable dosing, enabling adjustable drug release profiles for proprietary formulations targeting a broad range of indications [2] Investor Relations - The company utilizes its investor relations website and social media to disclose material non-public information and comply with disclosure obligations under Regulation FD [3] - Investors are encouraged to monitor the company's website and social media accounts for updates, press releases, SEC filings, and public conference calls [3]

Core Insights - Ligand Pharmaceuticals will report its first quarter 2025 financial results on May 8, 2025, before U.S. market opening [1] - A conference call will be held on the same day at 8:30 AM ET to discuss the results and provide a business update [2] Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing [3] - The company aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [3] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [3] - The company operates two royalty-generating technology platforms: Captisol® for drug solubility and stability, and NITRICIL™ for tunable dosing and adjustable drug release profiles [3] - Ligand has established alliances with major pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]

Core Viewpoint - The proposed merger between Ligand Pharmaceuticals and Channel Therapeutics aims to enhance the commercialization of Pelthos' ZELSUVMI™, a novel FDA-approved drug for treating Molluscum contagiosum infections, with a capital raise of $50 million from strategic investors [2][4][6]. Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on enabling scientific advancement through financing and licensing technologies, aiming to create a diversified portfolio of revenue streams [14]. - Channel Therapeutics is a clinical-stage biotechnology company developing non-opioid therapeutics for pain management, with a focus on the NaV1.7 sodium ion-channel [12]. - Pelthos Therapeutics, a subsidiary of Ligand, is dedicated to commercializing innovative therapeutic products, including ZELSUVMI™ [10]. Product Details - ZELSUVMI™ (berdazimer) is a topical gel approved by the FDA in 2024 for the treatment of Molluscum contagiosum in patients aged one year and older, and is the first prescription therapy that can be applied at home [3][9]. - The product utilizes Pelthos' proprietary nitric oxide-based technology platform, NITRICIL™, and is designed to be easy to use for patients, parents, and caregivers [5][9]. Market Opportunity - Molluscum contagiosum is a common skin infection affecting an estimated 16.7 million people in the U.S., with a significant unmet medical need for effective home treatment options [4][5]. - The merger is expected to provide near-term revenue generation opportunities from ZELSUVMI™ and advance Channel's existing pain treatment programs [4][6]. Transaction Details - The merger agreement stipulates that Channel will acquire 100% of Pelthos' equity interests, with Ligand investing $18 million and the investor group contributing $32 million, totaling $50 million [6][7]. - The combined company will operate under the name Pelthos Therapeutics Inc. and will be listed on the NYSE American under the ticker PTHS [2][7]. Leadership Structure - Following the merger, Scott Plesha will serve as CEO of the combined company, while Frank Knuettel II will take on the role of CFO [7].

Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare- dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformatio ...

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami). Management will participate in one-on-one meetings on March 10, 2025. Barclays 27th Annual Global Healthcare Conference (Miami). Management will participate in a fireside chat on March 12, 2025 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - CEO Paul Hadden - Senior Vice President of Investments and Business Development Tavo Espinoza - Chief Financial Officer Lauren Hay - Vice President of Strategic Planning and Investment Analytics Conference Call Participants Matt Hewitt - Craig-Hallum Joseph Pantginis - HC Wainwright Douglas Miehm ...

Financial Data and Key Metrics Changes - Ligand reported total revenue of $167 million for 2024, a 27% increase from $131.3 million in 2023 [25] - Royalty revenue grew by 28% to $108.8 million from $85 million in 2023, primarily driven by FilSpari and CarXiva [25] - Core adjusted EPS increased by over 40% to $5.74 per share [6][25] - Operating cash flow exceeded $100 million in 2024 [7] - GAAP net loss for 2024 was $4 million, compared to a net income of $53.8 million in 2023 [27] - Adjusted net income for 2024 was $156 million or $8.25 per diluted share, compared to $107.4 million or $6.09 per diluted share in 2023 [28] Business Line Data and Key Metrics Changes - Royalty revenue in Q4 2024 increased by 55% to $34.8 million from $22.5 million in Q4 2023 [28] - FilSpari sales totaled $132 million in 2024, generating approximately $12 million in royalty proceeds for Ligand [26] - Captisol sales were $30.9 million in 2024, up from $28.4 million in 2023 [26] Market Data and Key Metrics Changes - Recordati reported sales of Carceba at EUR 227 million in 2024, a 13% increase from 2023 [33] - Filspari's sales in Q4 2024 reached $50 million, a 40% increase compared to Q3 2024 [36] - Otuvare sales in Q4 were $36 million, significantly surpassing consensus estimates [37] Company Strategy and Development Direction - Ligand is focused on acquiring differentiated royalty assets and maintaining a low operating expense structure [6][12] - The company aims for a long-term royalty revenue growth rate of 20% CAGR from 2024 to 2029 [14] - Ligand's strategy includes investing in high-growth, low OpEx assets, with a strong emphasis on risk-reward opportunities [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future prospects, citing a robust business development pipeline and strong financial position [15][44] - The company anticipates continued growth in royalty revenue, particularly from FilSpari and Otuvare [36][38] - Management highlighted the significant unmet need in the COPD market and the potential for Otuvare to capture a large share [85] Other Important Information - Ligand ended 2024 with $256 million in cash and investments, with access to a $125 million revolving credit facility [7][25] - The company has restructured its business model to focus on profitable and compounding growth, reducing cash operating expenses by over 50% [11] Q&A Session Summary Question: Is the recent investment into Castle Creek Ligand's first move into cell and gene therapies? - Yes, it is Ligand's first cell and gene therapy investment, and the company is open to more opportunities in this area [48] Question: What is the expected impact of the SQ Innovations, Lasix launch on Captisol sales? - Captisol will see some sales from SQ Innovations, but it will not be a major contributor [53] Question: How does the DeFi deal signal Ligand's ability to do more syndicated deals? - Ligand will syndicate deals when necessary, focusing on maintaining a diversified risk portfolio [56] Question: What is the expected financial impact of the termination letter to Kasi on Ligand? - There is no expected material impact for 2025, as the licensing agreement with Acrotech will continue [106] Question: How has the opportunity set changed since the last update? - There has been an uptick in the pipeline, with a disciplined approach to selecting high-value opportunities [110]

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.25 1 A reconciliation of forward-looking non-GAAP adjusted earnings per diluted share to the most directly comparable GAAP measure is not available without unreasonable effort, as certain items cannot be reasonably predicted because of thei ...

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2024, and provided an operating forecast and business updat ...